Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era

Andrew M. Evens, DO, MSc, Irene Helenowski, MS, Chadi Nabhan, MD, FACP, Erika Ramsdale, MD, June M McKoy, MD, JD, MPH, MBA, Annette Larsen, B.A., R.N., Sarah Miyata, RN, MSN, ACNP, Benjamin Parsons, DO, Reem Karmali, MD, Britt E. Hanson, DO, Leo I. Gordon, MD, FACP, Scott E. Smith, MD, PhD, FACP, Stephanie A. Gregory, MD, Sonali M. Smith, MD

Blood (2011) 118 (21): 2625.

https://doi.org/10.1182/blood.V118.21.2625.2625

Published: 2011

Journal Articles

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),

Andres Forero-Torres, MD, R. Brian Berryman, MD, Ranjana H. Advani, MD, Nancy L. Bartlett, MD, Robert W. Chen, MD, Michelle A. Fanale, MD, Ajay K. Gopal, MD, Owen A. O'Connor, MD, PhD, Randal Olshefski, MD, Scott E. Smith, MD, PhD, FACP, Laurie E. Grove, PA-C, Jeffrey Matous, MD

Blood (2011) 118 (21): 3711.

https://doi.org/10.1182/blood.V118.21.3711.3711

Published: 2011

Journal Articles

Multicenter Analysis of Very Elderly Indolent and Aggressive Non-Hodgkin Lymphoma (NHL): Impact of Functional Status on Outcome,

Chadi Nabhan, MD, FACP, Sonali M. Smith, MD, Irene Helenowski, MS, Erika Ramsdale, MD, Reem Karmali, MD, Benjamin Parsons, DO, Josephine L. Feliciano, MD, Britt E. Hanson, DO, Scott E. Smith, MD, PhD, FACP, Annette Larsen, B.A., R.N., June M. McKoy, MD, MPH, JD, MBA, Stephanie A. Gregory, MD, Andrew M. Evens, DO, MSc

Blood (2011) 118 (21): 3668.

https://doi.org/10.1182/blood.V118.21.3668.3668

Published: 2011

Journal Articles

Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Azra Raza, MD, Naomi Galili, Ph.D., Deborah Mulford, MD, Scott E. Smith, MD, PhD, FACP, Gail Brown, MD, Lisa Meng, PhD, David P. Steensma, MD, Roger M. Lyons, MD, Ralph Boccia, MD, Mikkael A. Sekeres, MD, MS, Guillermo Garcia-Manero, Ruben A. Mesa, MD

Blood (2011) 118 (21): 2778.

https://doi.org/10.1182/blood.V118.21.2778.2778

Published: 2011

Journal Articles

Title: Promoter Methylation of Selected Genes and Response to Azacitidine (AZ) Therapy in Patients with Non-BCR-ABL Myeloproliferative Disorders (MPDs)

Nicholas Achille, BS, Laura Michaelis, MD, Scott E. Smith, MD, PhD, FACP, Eliza Germano, Nancy J. Zeleznik-Le, PhD, Sucha Nand, MD

Blood (2011) 118 (21): 4625.

https://doi.org/10.1182/blood.V118.21.4625.4625

Published: 2011

Journal Articles

Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Robert Chen, Ajay K. Gopal, MD, Scott E. Smith, MD, PhD, FACP, Stephen M. Ansell, MD, PhD, Joseph D. Rosenblatt, MD, Richard Klasa, MD, CM, FRCP(C), Joseph M. Connors, MD, Andreas Engert, MD, Emily K. Larsen, MS, Dana A. Kennedy, PharmD, Eric L. Sievers, MD, Anas Younes, MD

Blood (2010) 116 (21): 283.

https://doi.org/10.1182/blood.V116.21.283.283

Published: 2010

Journal Articles

High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)

Tulio E. Rodriguez, M.D., Patrick J. Stiff, MD, Scott E. Smith, MD, PhD, FACP, Jonathan L. Kaufman, MD, Mary Lee, RN, Mala Parthasarathy, MS, Zachary M. Earley, Sagar Lonial, MD, David H. Vesole, MD, PhD

Blood (2010) 116 (21): 1355.

https://doi.org/10.1182/blood.V116.21.1355.1355

Published: 2010

Journal Articles

Phase 1 Dose Escalation Study of TLK199 Tablets (Telintra), a Novel Glutathione Analog, in Myelodysplastic Syndrome.

Azra Raza, MD, Magda Melcert, MD, Naomi Galili, PhD, Scott E. Smith, MD, PhD, FACP, John E. Godwin, MD, MS, Shelby Young, RN, Lisa Meng, MS, Marsha Jones, MD, Gail L. Brown, MD, Jeffery Lancet, MD, Alan List, MD

Blood (2007) 110 (11): 1454.

https://doi.org/10.1182/blood.V110.11.1454.1454

Published: 2007

NARROW

Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),

Multicenter Analysis of Very Elderly Indolent and Aggressive Non-Hodgkin Lymphoma (NHL): Impact of Functional Status on Outcome,

Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Title: Promoter Methylation of Selected Genes and Response to Azacitidine (AZ) Therapy in Patients with Non-BCR-ABL Myeloproliferative Disorders (MPDs)

Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma

High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)

Phase 1 Dose Escalation Study of TLK199 Tablets (Telintra), a Novel Glutathione Analog, in Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only